Sapanisertib - Takeda Oncology

Drug Profile

Sapanisertib - Takeda Oncology

Alternative Names: HY-13328; INK-128; MLN-0128; TAK-228

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellikine
  • Developer Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); M. D. Anderson Cancer Center; National Cancer Institute (USA); Takeda; Takeda Oncology
  • Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours; Soft tissue sarcoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
  • Phase I Cancer; Solid tumours
  • Discontinued Breast cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 27 Aug 2018 Takeda Pharmaceuticals International plans the DICE phase II trial for Ovarian, Fallopian tube, Peritoneal cancer and Endometrial cancer in United Kingdom (NCT03648489)
  • 03 Jul 2018 Millenium Pharmaceuticals completes a phase II trial in Breast cancer (combination therapy, second line or greater) in USA, France, Belgium (NCT02049957)
  • 02 Jul 2018 Millennium Pharmaceuticals and Takeda completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom, France, Spain, USA (PO) (NCT02327169)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top